Article
Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial.
EBioMedicine - 1 Aug 2026
Bittner Tobias, Lopera Francisco, Rios-Romenets Silvia, Schiffman Courtney, Clayton David, Hibar Derrek, Kollmorgen Gwendlyn, Dolton Michael, Poon Victor, Nguyen Jonas, Giraldo-Chica Margarita, Acosta-Baena Natalia, Espinosa Alejandro, Villegas Gustavo, Muñoz Claudia, Serna Laura, Alvarez Sergio, Protas Hillary, Luo Ji, Sohankar Javad, Chen Yinghua, Ghisays Valentina, Malek-Ahmadi Michael, Ashton Nicholas J, Denkinger Marisa N, Cai Yuqi, Xu Yi Ran, Ostaszewski Beth, Selkoe Dennis J, Alexander Robert C, Quiroz Yakeel T, Su Yi, Chen Kewei, Doody Rachelle S, Langbaum Jessica B, Tariot Pierre N, Sink Kaycee M, Reiman Eric M
Abstract excerpt
BACKGROUND: The Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial evaluated the biological, cognitive, and clinical effects of crenezumab, an anti-oligomeric and monomeric amyloid-beta (Aβ) monoclonal antibody, in 30-60-year-old PSEN1 E280A mutation carriers without cognitive impairment from the world's largest ADAD kindred, finding no significant treatment effects on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.